Spark Therapeutics (NASDAQ:ONCE) : Traders are bullish on Spark Therapeutics (NASDAQ:ONCE) as it has outperformed the S&P 500 by a wide margin of 1.81% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.26%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.58% in the last 1 week, and is up 3.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -9.12% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $71.75 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $51.44 and the 200 Day Moving Average price is recorded at $38.25.
The stock has recorded a 20-day Moving Average of 12.56% and the 50-Day Moving Average is 20.04%.
Spark Therapeutics (NASDAQ:ONCE): stock turned positive on Friday. Though the stock opened at $54.01, the bulls momentum made the stock top out at $55.49 level for the day. The stock recorded a low of $52.88 and closed the trading day at $55.43, in the green by 2.55%. The total traded volume for the day was 600,978. The stock had closed at $54.05 in the previous days trading.
In an insider trading activity,The officer (See remarks) of Spark Therapeutics, Inc., La Barge Joseph sold 3,000 shares at $52.36 on July 5, 2016. The Insider selling transaction had a total value worth of $157,080. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.